- Home
- SVRA
SVRA
Savara Inc.
as 11-07-2025 3:53pm EST
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Upcoming Earnings Alert:
Get ready for potential market movements as Savara Inc. SVRA prepares to release earnings report on 13 Nov 2025.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 527.2M | IPO Year: | N/A |
| Target Price: | $6.88 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.89 - $4.50 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Savara Announces Participation in Upcoming Investor Healthcare Conferences
MT Newswires
9 days ago
Savara Closes $149.5 Million Public Offering
Business Wire
9 days ago
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
Insider Monkey
10 days ago
What Does Wall Street Think About Savara Inc. (SVRA)?
Business Wire
a month ago
Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025
MT Newswires
2 months ago
Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating
Simply Wall St.
4 months ago
Savara Independent Director Acquires 177% More Stock
MT Newswires
5 months ago
Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.